cannabidiol

Overview

Cannabidiol (CBD) is a non-intoxicating cannabinoid derived from Cannabis sativa that has attracted substantial biomedical interest because of its broad pharmacological profile. In the recent literature provided, CBD is discussed as a candidate with anti-inflammatory, neuroprotective, anticonvulsant, and anticancer activity, with particular relevance to refractory epilepsy, ischemic stroke, hyperglycemia-associated phenotypes, and breast cancer. It is also being evaluated in drug-repositioning frameworks as a host-targeted compound across interconnected disease networks.

Mechanistically, the studies summarized here portray cannabidiol as a pleiotropic bioactive molecule rather than a single-target agent. Its reported effects include modulation of inflammatory pathways, potential lowering of blood glucose, seizure suppression, and neuroprotection. At the same time, the literature emphasizes practical limitations such as low potency, the need for high dosing, and safety concerns including drowsiness, gastric adverse effects, and potential hepatotoxicity. These features have motivated formulation research, analog development, and delivery strategies such as exosomes and nanoparticles.

Focus of Latest Publications

Recent publications on cannabidiol have focused heavily on improving its delivery, bioavailability, and therapeutic performance through formulation strategies and combination approaches. Several studies examined cannabidiol in lipid-based, amorphous, or vesicular systems, including nanostructured lipid carriers with piperine, hot-melt-extruded PVP K30-phosphatidylcholine dispersions, exosome-based oral delivery, and multifunctional nanoparticles. Across these reports, cannabidiol was paired with carriers or co-ingredients to address its poor oral solubility and absorption. The piperine co-delivery study found that cannabidiol bioaccessibility depended strongly on the cannabidiol source, and that piperine codelivery with cannabidiol isolate doubled systemic exposure in mice. Similarly, amorphous polymer-phospholipid dispersions substantially increased cannabidiol solubility, dissolution, and in vitro permeability, while exosomal and folic acid-functionalized exosomal formulations improved tumor targeting and oral anticancer performance in breast cancer models.

Other recent work explored cannabidiol in disease-directed preclinical models, especially those involving inflammation, pain, neuroprotection, and tissue repair. In osteoarthritis, a microfluidics-enabled nanoparticle preloaded with cannabidiol improved lubrication, reduced inflammatory cytokines, preserved cartilage matrix, and mitigated joint damage in vitro and in vivo, with transcriptomic evidence implicating downregulation of SCN9A and inhibition of Nav1.7-related pathways. In ischemic stroke, a macrophage membrane-coated nanoparticle carrying cannabidiol, polysaccharide, and apigenin reduced brain injury, neuroinflammation, and neuronal apoptosis in a rat middle cerebral artery occlusion model, with effects linked to inhibition of NLRP3/NF-κB signaling. In rheumatoid arthritis, cannabidiol was studied in combination with methotrexate, with the abstract reporting investigation of synergistic efficacy, safety, and mechanism through STAT3/NF-κB signaling and M1 macrophage polarization.

Several studies also evaluated cannabidiol in neurological, metabolic, and perioperative settings. In zebrafish seizure models, synthetic cannabidiol analogs were screened for antiseizure activity, with some analogs outperforming cannabidiol in suppressing pentylenetetrazole-induced seizures and reducing neural hyperactivity. In hyperglycemic zebrafish, cannabidiol co-exposure improved optomotor performance but did not significantly lower blood glucose, and it did not restore all retinal electrophysiological deficits, suggesting only partial mitigation of hyperglycemic sequelae. A neuropathic pain study examined a cannabidiol-enriched Cannabis sp. extract administered via the oral mucosa for two weeks and reported moderate reduction in cold hyperalgesia in rats. In veterinary anesthesia, perioperative full-spectrum cannabis oil containing cannabidiol and tetrahydrocannabinol reduced propofol and sevoflurane requirements and increased sedation scores in female dogs undergoing mastectomy and ovariohysterectomy, without observed clinical complications.

Clinical pharmacokinetic work has also continued to compare cannabidiol formulations in humans. A randomized crossover phase I study evaluated an encapsulated powdered emulsion formulation versus an oil-based formulation under fasted and fed conditions in healthy participants, focusing on pharmacokinetics, tolerability, and safety. Together, these recent publications portray cannabidiol as a compound being actively optimized for delivery and explored across diverse preclinical and translational contexts, with recurring themes of enhanced bioavailability, multimodal anti-inflammatory or neuroprotective activity, and formulation-dependent effects on efficacy.

Key Publications

• NEWJun Sedative and anesthetic-sparing effects of perioperative full-spectrum cannabis oil in female dogs undergoing unilateral mastectomy and ovariohysterectomy. (Veterinary research communications, 2026, PMID 42348039): "this study aimed to evaluate the sedative effects and reduction in anesthetic requirements of a full-spectrum cannabis oil (FSCO) containing cannabidiol (CBD) and tetrahydrocannabinol (THC) in female dogs undergoing mastectomy and ovariohysterectomy."
• NEWJun Effect of Piperine Codelivery on the Oral Bioavailability of Cannabidiol: Insights from In Vitro Digestion and In Vivo Pharmacokinetics. (Journal of agricultural and food chemistry, 2026, PMID 42311044): "This study investigated whether coencapsulation of cannabidiol (CBD) and piperine (PIP) in food-grade nanostructured lipid carriers (NLCs) enhances the CBD oral bioavailability."
• NEWJun Development and Characterization of Amorphous PVP K30-Phosphatidylcholine Dispersions for the Fixed-Dose Co-Delivery of Hesperetin and Cannabidiol Prepared by Hot-Melt Extrusion. (AAPS PharmSciTech, 2026, PMID 42315741): "Hesperetin and cannabidiol (CBD) are promising plant-derived bioactives whose oral performance is limited by poor aqueous solubility."
• NEWJun Microfluidics-Enabled Nanoparticle for Multiscale Synergetic Osteoarthritis Therapy. (ACS nano, 2026, PMID 42261255): "...a zein core preloaded with cannabidiol (CBD), for multiscale synergistic OA therapy."
• Jul Oromucosal Administration of a Cannabidiol-Enriched Cannabis sp. Extract for 2 Weeks Moderately Reduces Cold Hyperalgesia in Rats With Neuropathic Pain. (European journal of pain (London, England), 2026, PMID 42248695): "This study evaluated the effects of a cannabidiol (CBD)-enriched Cannabis sp. extract administered via the oral mucosa in a CNP model."
• May The impact of cannabidiol (CBD) in hyperglycemic zebrafish (Danio rerio). (PloS one, 2026, PMID 42118736): "Cannabidiol (CBD) is a cannabinoid known to lower inflammation and reduce blood glucose levels."
• May In Vivo Characterization of Synthetic Cannabidiol Analogs for Seizure Suppression in Zebrafish. (ACS chemical neuroscience, 2026, PMID 42085339): "Cannabidiol (CBD) shows promise for the treatment of neurological disorders, including refractory epilepsy, but its low potency necessitates high dosing, leading to side effects that include drowsiness, gastric issues, and potential hepatotoxicity."
• May Multifunctional Cannabidiol-Loaded Nanoparticles Based on Herbal-Derived Bioactive Materials Provide Enhanced Neuroprotection against Ischemic Stroke. (Molecular pharmaceutics, 2026, PMID 42003696): "This nanoformulation (designated as CBDNPs) integrates polysaccharide for immunomodulation, apigenin for cardiovascular protection, and CBD for neuroprotection into a unified therapeutic strategy for the treatment of ischemic stroke."
• Jun Cannabidiol synergizes with methotrexate to attenuate rheumatoid arthritis via STAT3/NF-κB signalling-mediated M1 macrophage polarization. (International immunopharmacology, 2026, PMID 41955700): "Cannabidiol (CBD) is a nonpsychotropic cannabinoid that has powerful therapeutic efficacy in alleviating pain and inflammation, as well as favourable safety and tolerability profiles."
• May Comparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru®, vs an Oil-Based Formulation, Epidyolex®, Under Fasted and Fed Conditions in Healthy Participants: A Randomized Open-Label Cross-Over Phase I Study. (CNS drugs, 2026, PMID 41888503): "Emerging evidence indicates that cannabidiol (CBD) may offer meaningful therapeutic benefits across neurological, pain, and psychiatric disorders."